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ABSTRACT 
Jin Hyup Lee: Circadian clock disruption improves the efficacy of chemotherapy              
through p73-mediated apoptosis                                         
(Under the direction of Aziz Sancar) 
 The circadian clock in mammalian organisms is generated by a transcription-
translation feedback loop (TTFL) which controls many biochemical pathways at the 
cellular level and physiology and behavior at the organismal level. Cryptochrome (Cry) is 
a key protein in the negative arm of the TTFL. It has been found that Cry mutation in 
cells with p53-null genotype increased their sensitivity to apoptosis by genotoxic agents. 
Here, I show that this increased sensitivity is due to upregulation of the p53 gene family 
member p73 in response to DNA damage. As a consequence, when tumors arising from 
oncogenic Ras-transformed p53-/- and p53-/-Cry1-/-Cry2-/- cells are treated with the 
anticancer drug, oxaliplatin, the p53-/- tumors continue to grow whereas the p53-/-Cry1-/-
Cry2-/- tumors exhibit extensive apoptosis and stop growing. This finding provides a 
mechanistic foundation for overcoming the resistance of p53-deficient tumor cells to 
apoptosis induced by DNA-damaging agents and suggests that disruption of 
cryptochrome function may increase the sensitivity of tumors with p53 mutation to 
chemotherapy. 
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Circadian Clock 
 A variety of biological systems in living organisms ensure proper adaptation to 
constantly changing environmental conditions. The most obvious conditions that affect 
most living organisms, from bacteria to humans, is the daily (circadian) light-dark cycle 
caused by the Earth’s rotation around its axis. To ensure proper adaptation to the 
circadian cycle, many organisms have developed a global regulatory system called the 
circadian clock that generates rhythmic changes with about 24-hr periodicity in many 
cellular and organismal functions (Bell-Pedersen et al., 2005; Lowrey and Takahashi, 
2004). Thus, in mammals, various physiological processes including the daily sleep and 
wake cycle, blood pressure, body temperature, feeding behavior, hormone secretion, drug 
and xenobiotic metabolism, glucose homeostasis, cell-cycle progression, and immune 
system activity demonstrate circadian oscillation even in the absence of environmental 
cues (Merrow et al., 2005). 
Following the initial discovery of circadian clock genes in mammals, it became clear that 
the expression of these genes was ubiquitous and has the capacity for generating circadian 
oscillations in various gene expressions in the majority of tissues throughout the body 
(Bell-Pedersen et al., 2005; Lowrey and Takahashi, 2004). It is now well established that 
the circadian clock is operative in virtually every cell and tissue and that clock function at 
the molecular level is determined by interlocking transcription-translation-based feedback 
loops (TTFL) that drive rhythmic RNA and protein expression of key clock components. 
At the molecular level the clock is comprised of 4 gene groups, CLOCK/NPAS2, BMAL1, 
11 
 
Cry1/2, and Per1/2, that generate a transcription-translation feedback loop (TTFL) (Fig. 1): 
The transcriptional activators CLOCK and BMAL1 proteins, which belong to the family of 
bHLH-PAS domain transcription factors, make a heterodimer that binds to E-box enhancer 
elements (CACGTG) in the promoter of the transcriptional repressor genes Cryptochrome 1 
and 2 (Cry1 and Cry2) and Period 1 and 2 (Per1 and Per2) and induces their transcription. 
The Cry and Per proteins, in turn, inhibit the CLOCK-BMAL1 after a time lag to close the 
regulatory loop and generate rhythmic expression or subcellular location of the clock proteins 
(Hastings et al., 2003; Reppert and Weaver, 2002; Sahar and Sassone-Corsi, 2009; Sancar, 
2008; Takahashi et al., 2008; Vitaterna et al., 1999). The time delay between the synthesis of 
the Per and Cry and their action as repressors is a key factor in generating an oscillatory 
pattern of expression of these proteins (Lee et al., 2001). The entire cycle takes 
approximately 24 hours to complete; however, little is known about the stoichiometry and 
kinetics of this feedback loop. In addition to the primary feedback loop, there is a second 
negative-feedback loop involving the nuclear hormone receptor Rev-Erbα, which is a direct 
target of CLOCK-BMAL1 and which strongly represses BMAL1 transcription (Preitner et al., 
2002; Sato et al., 2004). This secondary loop is not essential, but is thought to add robustness 
to the circadian clock (Gallego and Virshup, 2007; Lee et al., 2001). 
 In addition to the core components of circadian oscillatory machinery, the Clock-
BMAL1 complex drives the rhythmic expression of numerous clock controlled genes 
harboring E-box sequences in their promoters, providing a complex multilevel regulation of 
the circadian clock which ensures high plasticity of the system and enabling fast adaptation 
of the organism to its constantly changing environment (Grundschober et al., 2001; Lowrey 
and Takahashi, 2004; Panda et al., 2002; Storch et al., 2002). 
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Fig. 1. Mammalian molecular clock. BMAL1-CLOCK heterodimer binds to the E-boxes in 
the promoters of the PER and CRY genes, as well as in the clock-controlled genes, activating 
their transcription. After a time lag, the Per and Cry proteins dimerize, enter the nucleus and 
inhibit CLOCK-BMAL1-activated transcription of their own genes as well as of those of 
clock-controlled genes, thus generating an oscillatory pattern of gene expression. Adapted 
from (Hastings et al., 2003; Reppert and Weaver, 2002; Sahar and Sassone-Corsi, 2009; 
Sancar, 2008; Takahashi et al., 2008; Vitaterna et al., 1999). 
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Thus, the circadian clock system regulates physiology, behavior, and metabolism 
through periodic activation and repression of the set of clock-controlled genes (CCGs) that 
are involved in a remarkably wide variety of cellular pathways (Green et al., 2008; Sahar and 
Sassone-Corsi, 2009; Schibler and Sassone-Corsi, 2002). Global temporal transcriptional 
profiling of various tissues using microarray hybridization approaches has revealed that as 
much as 10% of mammalian transcriptome oscillate in a circadian manner (Panda et al., 
2002). Furthermore, these studies demonstrate remarkable tissue-specificity of circadian 
regulation with less than 5-10% overlap in clock-controlled genes between different tissues. 
 In many cases, tissue-specific clock-controlled genes were recognized to be involved 
in rate-limiting steps that were distinct for the organ function (Panda et al., 2002; Storch et al., 
2002). In addition to their primary role in the generation of circadian rhythms, recent work 
has shown that circadian clock genes can affect a wide variety of other physiological 
processes. Accordingly, the clock network is integrated within all of the major cellular 
signaling and metabolic pathways (Hastings et al., 2003; Sahar and Sassone-Corsi, 2009; 
Takahashi et al., 2008). As a consequence, disruption of the clock is expected to affect 
cellular and organismal behavior in multiple ways. Emerging examples of circadian 
regulation of physiological pathways include diverse aspects of cellular metabolism, cell 
growth and DNA-damage control, xenobiotic responses, and the modulation of behavioral 
responses to drugs and alcohol. Thus, it has been widely recognized that these periodic 
rhythms are capable of responding to environmental changes to coordinate the phases of the 
endogenous clocks with intracellular or extracellular environment. 
Cryptochrome 
 Cryptochrome (Cry) is a flavoprotein that regulates growth and development in plants 
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in response to blue light, functions as a circadian photoreceptor in Drosophila and other 
insects, and acts as a core component of the molecular clock in mammalian organisms 
(Cashmore, 2003; Lin and Shalitin, 2003; Partch et al., 2005; Partch and Sancar, 2005; 
Sancar, 2004a, b). Cryptochrome exhibits 25-50% sequence identity to photolyase (Hsu et al., 
1996; Todo et al., 1996) and, like photolyases, contains both FAD and folate as cofactors 
(Lin et al., 1995; Malhotra et al., 1995). Most cryptochromes, including the human 
cryptochrome, have C-terminal extensions of 20–200 amino acids beyond the photolyase 
homology region.  Of all cryptochromes identified to date, the Arabidopsis cryptochrome is 
the best characterized. However, despite numerous findings indicative of a photoreceptor 
function of cryptochrome in Arabidopsis, the photochemical reaction in blue-light signaling 
by cryptochrome is not known and still the strongest evidence that Arabidopsis cryptochrome 
are blue-light receptors is their high degree of similarity to photolyase (Cashmore, 2003; Lin 
and Shalitin, 2003; Sancar, 2003). 
 Based on exhaustive biochemical data, it has been concluded that humans and other 
placental mammals do not have photolyase (Li et al., 1993). Therefore, the discovery of 
cryptochrome as a photolyase ortholog by the human genome project was rather surprising 
and necessitated reevaluation of the issue of photolyase in humans. These studies 
demonstrated that neither this protein nor a second ortholog our group subsequently 
discovered had photolyase activity and suggested that these proteins must therefore perform 
other blue light-dependent functions in human cells (Hsu et al., 1996). Taking into account 
the information available on circadian photoreception at the time, it was proposed that these 
proteins may function as circadian photoreceptors (Hsu et al., 1996). 
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To test the hypothesis that cryptochrome functions as circadian photoreceptors, the 
expression pattern of Cry1 and Cry2 was analyzed. Cryptochrome was found to be expressed 
in all tissues; however, expression was high in the retina and restricted to the inner retina in 
both mice and humans (Miyamoto and Sancar, 1998, 1999; Thompson et al., 2003). In the 
brain of mice, Cry1 was highly expressed in the anterior hypothalamus in a cluster of neurons 
called the suprachiasmatic nuclei (SCN), and expression exhibited a daily oscillation, 
peaking at about 2:00 p.m. and reaching its nadir at around 2:00 a.m. (Miyamoto and Sancar, 
1998, 1999). Thus, it appeared that cryptochrome was expressed in the appropriate places for 
setting the clock and for running it and gave credence not only to the hypothesis that 
cryptochrome is a circadian photoreceptor but also raised the possibility that cryptochrome is 
a component of the molecular clock (Miyamoto and Sancar, 1998). Subsequently, 
cryptochrome was found in Drosophila and all other insects tested as well as Xenopus and all 
other vertebrate animals whose genomes have been sequenced (Hall, 2000; Sancar, 2000; 
Todo, 1999). 
At present, there is no crystal structure of any animal cryptochrome. Molecular 
modeling of the human Cry2 photolyase homology region using the structure of Arabidopsis 
Cry1 as a template (Brautigam et al., 2004) reveals a photolyase-like structure including the 
positively charged DNA-binding groove (Fig. 2) (Brautigam et al., 2004; Ozgur and Sancar, 
2003; Sancar, 2004b). Both human Cry1 and Cry2 bind with moderate affinity to DNA and 
with higher affinity to UV light-damaged DNA but have no repair activity (Ozgur and Sancar, 
2003). 
The DNA binding activity of cryptochrome might be an evolutionary relic of its 
common ancestry with photolyase. In contrast to these biochemical activities of obscure 
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Fig. 2. Structures of photolyase and cryptochrome. Left, crystal structure of E. 
coli photolyase; right, the computer-generated structure of human cryptochrome 2. Yellow, 
FAD; green, MTHF. Adapted from (Ozgur and Sancar, 2003; Sancar, 2004b). 
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significance, human cryptochrome interacts strongly with several “clock proteins” to 
generate a transcriptional feedback loop called the circadian clock (Reppert and Weaver, 
2002; Young and Kay, 2001). The first direct evidence that cryptochrome plays a role in the 
circadian clock came from the analysis of mice in which the Cry2 gene was knocked out: 
Wild type mice in constant darkness exhibit a circadian rhythm of behavior with an intrinsic 
period of 23.7 h. The Cry2-/- mice exhibited a period about 1 h longer than wild type mice 
(Thresher et al., 1998). These data led to the conclusion that Cry2, in addition to any putative 
photoreceptor function, must have a light-independent role in the maintenance of the normal 
rhythm (Thresher et al., 1998). This conclusion was strengthened and extended by the 
analysis of mice lacking Cry1 or both Cry1 and Cry2 (van der Horst et al., 1999; Vitaterna et 
al., 1999); Cry1-/- mice have a period 1 h shorter than wild type mice and, most 
strikingly, Cry1-/-Cry2-/- (hereafter CryDKO) animals are arrhythmic. The cause of the drastic 
effect of the loss of cryptochrome became apparent when the molecular basis of the 
mammalian circadian rhythm was elucidated (Fig. 1) (Reppert and Weaver, 2002; Young and 
Kay, 2001). 
p73 Tumor Suppressor 
 One of the most significant advances in cancer biology in recent years has been the 
recognition of the importance of apoptosis in preventing oncogenically transformed cells 
from proliferation and hence from overt cancer (Johnstone et al., 2002). It appears that 
oncogenically transformed cells are more prone to apoptosis than normal cells (Junttila and 
Evan, 2009). The tumor suppressor protein p53 is a master regulator of the apoptotic cellular 
response to DNA damaging agents including many anticancer drugs (Fridman and Lowe, 
2003; Lowe et al., 1994; Lowe et al., 1993; Meulmeester and Jochemsen, 2008; Symonds et 
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al., 1994). However, cancers with intact p53 function are in a minority. Indeed, at least 50% 
of human cancers lack functional p53 (Vogelstein et al., 2000). Furthermore, lack of p53 
activity in tumor cells causes resistance to chemo- and radiotherapies and thereby contributes 
to the progression of the tumor to a more malignant phenotype (Cohen et al., 2005; Lowe et 
al., 2004; Munro et al., 2005; Schmitt et al., 2002). Nonetheless, p53-deficient cancer cells 
still leave intact latent potential to undergo apoptosis, implying the existence of other 
mechanisms of apoptosis (Hollstein et al., 1999; Roos et al., 2004). Thus, elucidation of this 
tumor-suppressive mechanism is considered to be important for developing strategies to treat 
p53 mutant tumors. 
 Investigation of activating p53-related signaling in the absence of any form of p53, 
structural and functional homologues of the p53 tumor suppressor, p73 and p63, which are 
also transcription factors, have been identified (Kaghad et al., 1997; Yang et al., 1998). 
Although p63 and p73 exhibit limited sequence homology with p53 in the N-terminal 
transactivation domain (TAD) and the C-terminal oligomerization domain (OD), both share 
approximately 60% similarity with the central DNA-binding domain (DBD) of p53, 
including conservation of essential DNA contact residues (Yang et al., 2002). This similarity 
allows p63 and p73 to regulate p53 target genes and, similar to p53, to induce cell cycle 
arrest and apoptosis (Danial and Korsmeyer, 2004; Urist and Prives, 2002; Yang et al., 2002). 
Gene knockout studies have shown that in contrast to p53, p63 and p73 play essential roles in 
development as homozygous knockout of either gene causes embryonic lethality (Mills et al., 
1999; Yang et al., 1999; Yang et al., 2000). 
In addition to their roles in development, the p53 family members p63 and p73 have 
been linked to tumor suppression through pro-apoptotic function (Agami et al., 1999; Flores 
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et al., 2005; Gong et al., 1999; Irwin and Kaelin, 2001; Jost et al., 1997; Stiewe and Putzer, 
2000; Yang et al., 1998; Yuan et al., 1999). It has been reported that in the absence of p53, 
p73 substitutes p53 functions that trigger apoptosis (Irwin et al., 2003). This finding suggests 
that p73 is a key player in cellular response to anticancer drugs in tumor cells that lack 
functional p53. Indeed, inhibition of p73 function by dominant-negative p73 variants or small 
interfering RNA (siRNA) reduces the cytotoxicity of genotoxic drugs (Irwin et al., 2003; Lin 
et al., 2004). These studies support a model in which in the absence of p53, the functional 
status of p73 is an important determinant of cellular sensitivity to anticancer drugs. Recent 
work has shown that p73 is induced by a wide range of chemotherapeutic drugs, 
including cisplatin, doxorubicin, taxol, and camptothecin (Agami et al., 1999; Costanzo et al., 
2002; Gong et al., 1999; Irwin et al., 2003). 
Moreover, efforts directed at functional screening for small molecules that restore p53 
transcriptional responses in p53-deficient cells suggest that the p73 can promote apoptosis in 
p53-deficient cells as an important therapeutic target (Wang et al., 2006). Specifically, small 
molecules that increase expression of p73 restore proapoptotic effects normally observed 
downstream of wild-type p53 activation by classic therapeutic agents. In addition, the fact 
that p73 is rarely genetically and epigenetically altered in cancer means it provides a window 
of opportunity for treatment by increasing p73 expression in nearly all tumor types (Melino 
et al., 2002; Melino et al., 2003). Moreover, recent preclinical data show that breast cancer 
patients with high expression of p73 appear to exhibit increased sensitivity to platinum-based 
chemotherapy (Leong et al., 2007). 
Cryptochrome/Carcinogenesis/Apoptosis 
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 Work in our lab on circadian clock-cancer connection revealed that Cry mutation 
does not predispose mice to spontaneous or IR-induced cancers (Gauger and Sancar, 2005) 
and that in p53-null background Cry mutation reduced cancer risk (Ozturk et al., 2009). I 
wished to understand the mechanism by which Cry mutation reduced cancer risk in p53-null 
animals. 
I found that circadian clock disruption by Cry mutation (Ozturk et al., 2009) or Cry 
downregulation in a p53-null (Lowe et al., 1994; Lowe et al., 1993) background renders cells 
more sensitive to genotoxic agents, such as UV, by making them more prone to apoptosis 
(Fig. 3; Fig. 4) (Ozturk et al., 2009). To gain some insight into the mechanism by which Cry 
mutation sensitizes cells to apoptosis we considered the p53-independent pathways for 
intrinsic apoptosis. 
 Specifically, I focused on contribution of the p73 gene to intrinsic apoptosis. The p73 
protein along with p63 and p53 constitute the p53 family (Melino et al., 2003; Stiewe, 2007; 
Yang et al., 2002). Of these, p53 is the primary tumor suppressor which prevents cancer 
mainly by promoting apoptosis in response to DNA damage or oncogenic transformation. In 
the absence of p53, the other two members of the family, in particular p73, a structural and 
functional homolog of p53 (Melino et al., 2003; Stiewe, 2007; Yang et al., 2002), can 
substitute for p53 as the pro-apoptotic tumor suppressor (Flores et al., 2005; Gong et al., 
1999; Irwin et al., 2000; Irwin et al., 2003; Jost et al., 1997). 
 Hence, when I discovered that p53-/-Cry1-/-Cry2-/- (hereafter p53KOCryDKO) cells have 
increased sensitivity to apoptosis compared to p53-/- (p53KO) cells (Ozturk et al., 2009), I 
reasoned that this might have been caused by an elevated level of p73 in p53KOCryDKO, in 
particular after DNA damaging treatment as it is known p73 is a damage-inducible gene 
 
 
21 
(Marabese et al., 2003). To test this idea I compared the p73 levels and apoptosis in p53KO 
and p53KOCryDKO cells after UV irradiation or oxaliplatin treatment. I found that these 
genotoxic treatments induce high levels of p73 in cryptochrome mutant cells and 
significantly enhance apoptosis and clonogenic cell death in p53KOCryDKO cells relative to 
p53KO cells. Finally, I demonstrated that the circadian clock regulates p73 activity through C-
EBPα and Egr1 in the response to DNA damage. These findings suggest that disruption or 
inhibition of cryptochrome function may be used as an adjuvant in cancer chemotherapy with 
platinum-based drugs. 
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Fig. 3. p53-null and Cry-deficient cells are more sensitive to UV-induced apoptosis and 
clonogenic death than p53KO cells. (A) Apoptosis. Unirradiated (-) or irradiated (2,5,10,20 
Jm-2) cells of the indicated genotypes were harvested 24 hrs post-irradiation, lysed and 
analyzed by immunoblotting. (B) Clonogenic survival. Cells of the indicated genotypes, 
transfected with indicated siRNAs for 48 hrs, were irradiated with the indicated UV dose and 
then incubated for 9-10 days until colonies were readily visible. Results represent the means 
of 3 independent experiments (±s.d.). From (Ozturk et al., 2009) 
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Fig. 4. Increased UV-killing of p53-null and Cry-null cells is due to enhanced apoptosis. 
Cells of the indicated genotypes were preincubated for 2 hrs with the caspase 3 inhibitor, Z-
DEVD-FMK, where indicated, irradiated with 10 Jm-2 and analyzed for apoptosis and UV 
survival. (A) Apoptosis. The maximum value of cleaved PARP was set to 100% and other 
values are plotted relative to the maximum. (B) UV survival. Standard clonogenic assay was 
used to obtain percent survival. Means (±s.d.) of 3 independent experiments. 
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MATERIALS AND METHODS 
Establishment of p53KO and p53KOCryDKO Tumor Cell Lines 
 The cell lines were generated from the p53KO and p53KOCryDKO mouse strains as 
described previously (Gauger and Sancar, 2005; Ozturk et al., 2009). To obtain cell lines, 
skin patches from the back of mice at the age of 3 months were taken under sterile conditions, 
cut into small pieces, placed into 4 or 6 well-plates and incubated for one week to let the 
fibroblasts migrate into the wells. The fibroblasts were passaged at least 3 times before using 
them in any experiments. Primary wild-type skin fibroblasts were isolated in the same 
manner, and passaged 8 times without the appearance of spontaneously immortalized clones. 
Wild-type mouse embryonic fibroblasts were kindly provided by Dr. Norman Sharpless 
(University of North Carolina). For Ras-induced oncogenic transformation, cells were seeded 
into 10 cm plates, and transfected with 250 ng of pEGFP-N1 (Clontech), and/or 5 µg 
of Ras pT24 vector (Ozturk et al., 2009) using FuGENE 6 reagent (Roche). The next day, 
cells were split into 3 plates, and incubated for 18 days. The plates were stained with Giemsa 
and colonies of oncogenically transformed cells were counted visually and the fraction of 
transformed cells was normalized for transfection efficiencies calculated by counting GFP 
positive cells in each plate. These cells were maintained in DMEM (Life Technologies, 
Gaithersburg, MD) supplemented with 10% fetal bovine serum (Gemini, Woodland, CA) and 
100 units/mL penicillin and 100 µg/mL streptomycin (Life Technologies). The cells were 
maintained in an incubator at 37°C under 5% CO2. The CryDKO cell line has been described 
(Gauger and Sancar, 2005). 
Human Cell Lines 
The H1299 cells were kindly provided by Dr. Shlomo Melmed (Cedars-Sinai Medical  
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Center, LA).  Caco-2 and A549 cells were obtained from American Type Culture 
Collection (ATCC). These cells were grown in DMEM with 10% FBS and 100 units/mL 
penicillin and 100 µg/mL streptomycin at 37°C under 5% CO2. 
Clonogenic Survival Assay 
 UV survival assays were performed as described previously (Gauger and Sancar, 
2005) using a fluence in the range of 0-10 Jm-2. For oxaliplatin survival assays, cells were 
seeded into 6-well plates at 105, 5×104, and 2×104 cells per well in duplicate and incubated in 
growth medium for 10 to 14 hrs. The cells were washed and incubated with 0-20 µM 
oxaliplatin for 2 hrs. Then, the cells were washed with PBS twice, growth medium was added 
and cells were incubated for 10 to 14 days. Cells were then fixed for 20 min in 3:1 
methanol/acetic acid, rinsed with water, and stained with 5% methylene blue, and counted. 
Colonies containing >50 cells were scored and survival was calculated from the ratio of the 
number of colonies in the treated samples to those in the control plates. 
Immunoblot Analysis 
 Antibodies were from the following sources: Egr1, PARP, cleaved Caspase 3, p53 
(Cell Signaling Technology), p63 (Novus Biologicals), p73 (Upstate), C-EBPα (Thermo 
Scientific), and Actin, Cyclophilin B (Santa Cruz Biotechnology). Mouse Cry1 (monoclonal) 
and Cry2 (polyclonol) antibodies were made in our laboratory (Gauger and Sancar, 2005). 
Conventional immunoblotting procedures were used to detect the target proteins: Cells were 
collected, washed once in cold PBS and then scraped in TEGN buffer (10 mM Tris at pH 8, 1 
mM EDTA, 10% glycerol, 0.5% NP40, 400 mM NaCl, 1 mM DTT, 0.5 mM 
phenylmethylsulfonylfluoride, and protease inhibitor mixture containing 1 M Benzamidine, 3 
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mg/mL Leupeptin, 100 mg/mL Bacitracin, and 1 mg/mL α2 macroglobulin) and incubated on 
ice for 15 min. Lysates were then cleared by centrifugation at 20,000 g for 10 min. Total 
protein concentration was determined via the Bio-Rad protein assay (Bio-Rad Laboratories). 
Equal amounts of protein were separated on 10% SDS-PAGE and the proteins were 
transferred to nitrocellulose membranes (Schleicher and Schuell). The membranes were then 
blocked for 1 hr in a PBS solution containing 5% nonfat milk powder and 0.1% Tween-20 
and then probed with primary antibody overnight in 1% milk, 0.1% Tween-20 in PBS. After 
washing, membranes were incubated for 1 hr with horseradish peroxidase-linked secondary 
antibody (Sigma) in 1% milk, 0.1% Tween-20 in PBS. Finally, after three 5-min washes in 
0.1% PBS-Tween 20, proteins were visualized by enhanced chemiluminesence (Amersham 
Biosciences). Band intensities were quantified with ImageQuant 5.2 software (Molecular 
Dynamics). 
Chromatin Immunoprecipitation 
 ChIP was performed by manufacturer’s instruction (Sigma) with some exceptions. 
Protein-DNA complexes incubated with rabbit polyclonal antibodies against BMAL1 (Bethyl 
Laboratories, Inc.), rabbit monoclonal antibody directed against Egr1 (44D5, Cell Signaling 
Technology), rabbit polyclonal antibody against C-EBPα (PA1-825, Thermo Scientific), or 
equivalent IgG control (Cell Signaling Technology) were precipitated using protein A/G-
conjugated agarose beads (Calbiochem). Protein-DNA crosslink was resolved and followed 
by quantitative real-time PCR (qPCR) using sybr green master mix (Applied Biosystems) 
with the primers listed in Table 1. 
Chemicals and Treatment 
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 Cells were treated with 20 µg/ml cycloheximide (Sigma) or 5 µg/ml actinomycin D in 
DMEM as indicated and then protein stability was assayed by conventional immunoblotting. 
The caspase 3 inhibitor Z-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-CH2F (Z-DEVD-FMK) 
(R&D systems, Inc.) was used at a final concentration of 25 µM. 
RNA Interference and Transfection 
 For RNAi experiments, cells at 70% confluency were transfected using DharmaFECT 
(Dharmacon Research Inc.) according to the manufacturer’s directions for transfection of 
ON-TARGET plus SMARTpool small interfering RNA (siRNA) duplexes specific for each 
target purchased from Dharmacon Research Inc; mouse Cry1 (L-040485-01-0005), mouse 
Cry2 (L-040486-00-0005), mouse Per1 (L-040487-00-0005), mouse Per2 (L-040489-01-
0005), mouse BMAL1 (L-040483-01-0005), mouse Egr1 (L-040286-00-0005), mouse C-
EBPα (L-040561-00-0005), mouse p73(L-043871-00-0005), mouse cyclophilin-B (D-
001820-20-05) as a control, human Cry1 (L-015421-00-0005), human Cry2 (L-014151-01-
0005), human cyclophilin-B (D-001820-10-05) as a control, or non-targeting siRNA (D-
001810-10-05) as a control. The siRNA experiment was carried out for 48 hrs, at which time 
cells were harvested and the extent of knockdown of the target genes was assessed by 
immunoblotting or RT-PCR. For the determination of the effect of gene knockdown on 
clonogenic survival, after treating the cells with siRNA for 24 hrs, the cells were plated at 
low density to ensure the formation of 400 colonies per 6-well plate in the absence of UV 
irradiation. Following plating, cells were incubated in growth medium for 10 to 14 hrs and 
treated with UV at a fluence rate of 0.5 Jm-2sec-1 from a germicidal lamp for the appropriate 
doses. The cells were then incubated for 9 to 10 days until colonies were readily visible. The 
specificity of the antibodies and siRNAs used are shown in Fig. 5. 
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RT-PCR 
 RNA was extracted from cell pellets using RNeasy Mini Kit (Qiagen) and quantified 
by UV-Vis spectrophotometry. The cDNAs were generated by reverse transcription with 
random hexamer using ImProm-II Reverse Transcription System (Promega). Then RT-PCR 
was performed with the primers listed in Table 2. qPCR was then performed using the 
Expand High Fidelity PCR system (Roche). Conditions for linear amplification were 
established through template and cycle curves. PCR products (40% of reaction mixture) were 
then separated on 2% agarose gels and bands were visualized with ethidium bromide staining. 
Quantification of p73 induction was performed with Image Quant 5.2 software (Molecular 
Dynamics). 
Tumor Xenograft Model 
 Animal studies were conducted in accordance with the regulations of the National 
Institutes of Health and the Institutional Animal Care and Use Committee of the University 
of North Carolina School of Medicine. Tumor xenografts were established in 6-week-old 
female immunodeficient NOD/SCID mice by subcutaneous inoculation of 2×106 cells mixed 
with an equal volume of matrigel (BD Biosciences) into both flanks. The NOD/SCID mice 
were bred and kept under defined-flora pathogen-free conditions at the AALAC-approved 
Animal Facility of the Division of Experimental Radiation Oncology, University of North 
Carolina. Oxaliplatin at 10 mg/kg was administered intraperitoneally once a week for 21 days. 
Tumor volume and body weight were recorded every 3 days. Tumor size was measured with 
a caliper in 3 mutually perpendicular diameters (a, b, and c) and the volume was calculated as 
V = (π/6)×a×b×c. 
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MicroPET Imaging 
 Whole-body images of the biodistribution of 18F-2-deoxyglucose ([18F]-FDG) tracers 
in mice was obtained by micro positron emission tomography (microPET) scans. Mice were 
kept warm, under gas anesthesia (2% isoflourane) and injected with [18F]-FDG 
intraperitoneally. A 1-h interval for uptake was allowed between probe administration and 
microPET scanning. Data were acquired using a Siemens Preclinical Solutions microPET 
Focus 220 instrument. MicroPET data were acquired for 10 min and was reconstructed using 
statistical maximum a posteriori probability algorithms (MAP) into multiple frames. The 
spatial resolution of microPET is approximately 1.5-mm, 0.4-mm voxel size. Three-
dimensional regions of interest (ROI) were drawn using AMIDE software (Andreas Loening). 
Color scale is proportional to tissue concentration with red being the highest and lower 
values in yellow, green, and blue. 
In Vivo Imaging of Caspase 3 Activity 
 For preparation of Z-DEVD-aminoluciferin, 10 mg of Vivo Glo Caspase 3/7 substrate 
(Promega) were dissolved in 67 µl of surfactant mix (70 µl of Tween 80, 640 µl of PEG 400, 
and 290 µl of N,N-dimethylacetamide) and then added to 100 µl of 5% glucose in water. The 
mixture was vortexed to make a homogenous suspension and injected intraperitoneally into 
tumor-bearing mice (100 µl/mouse). 10 minutes after Z-DEVD-aminoluciferin injection, the 
mice were imaged with IVIS-200 (Xenogen Corp) for the in vivo photon counting of 
bioluminescence. The photon emission intensity (photons/second) of each mouse is indicated 
in a rainbow bar scale. 
Statistical Analysis 
 
 
31 
 Results are shown as mean ± SD, which were performed using 2-tailed t test. 
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Fig. 5. Specificity and efficiency of siRNAs used to downregulate apoptosis and clock 
genes. (A to D) Mouse cell lines. (E and F) Human cell lines. When available, antibodies 
were used to monitor downregulation; otherwise RT-PCR was employed for the mRNAs of 
target genes. 
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RESULTS 
Effect of Cryptochrome Mutation on p73 Expression 
 I found that under our assay conditions neither p73 nor p63 are detectable before 
DNA damage but both are strongly induced after UV irradiation (Fig. 6A). Importantly, 
however, while the Cry mutation in p53-null background had no effect on p63 induction by 
UV it enhanced the rates of both p73 mRNA and protein synthesis by a factor of about 10 
(Fig. 6B). I should note, however, that the enhanced induction of p73 by UV in p53KOCryDKO 
cells is not unique to cells with p53-null genotype. I found essentially the same dose response 
and enhanced induction of p73 in CryDKO cells as in p53KOCryDKO cells (Fig. 7), indicating 
that enhanced expression of p73 in Cry-null cells is independent of the p53 status of the cell. 
 To ascertain that the enhanced apoptosis in p53KOCryDKO was in fact dependent upon 
p73, I compared the UV-induced apoptosis in p53KOCryDKO and p53KO cells before and after 
siRNA knockdown of p73. The results indicate that both the residual apoptosis observed in 
p53KO and the enhanced apoptosis seen in p53KOCryDKO cells are drastically reduced when 
p73 is downregulated (Fig. 8), suggesting that the enhanced induction of p73 in p53KOCryDKO 
is responsible for the increased apoptosis seen in these cells. 
Regulation of p73 by the Circadian Clock 
 These findings suggest a unique regulatory mechanism that is both circadian clock- 
and DNA damage-dependent. To test this model I analyzed p73 levels and apoptotic response 
to DNA damage in p53KO cells after downregulation of the negative (Cry1/2 or Per1/2) and 
positive (BMAL1) elements of the core circadian TTFL. 
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Fig. 6. p73 induction is amplified in p53KOCryDKO cells. Time course of p73 induction in 
p53KO and p53KOCryDKO cells analyzed by immunoblotting and RT-PCR. The quantitative 
results of the levels of p73 protein and mRNA, shown in the bottom panel, are means ±s.d. 
(n=3). The UV dose was 10 Jm-2. 
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Fig. 7. p73 is highly induced in Cry-null cells by UV irradiation. Cells of the indicated 
genotypes were irradiated with 10 Jm-2 and harvested at the indicated time points. p73 
induction was probed by immunoblotting or RT-PCR, using Actin and GAPDH as loading 
controls. 
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Fig. 8. Enhanced apoptosis in p53KOCryDKO cells is dependent upon p73. Immunoblots 
showing the role of p73 in UV-induced apoptosis in p53KOCryDKO cells. Cells were 
transfected with the indicated siRNAs, irradiated with 10 Jm-2 and then analyzed for 
apoptosis by probing for cleaved PARP (c-PARP) and cleaved caspase 3 (c-Casp3). 
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The results are shown in Fig. 9, and Fig. 10. Downregulation of either Cry1/2 or Per1/2 
enhances UV-induced p73 synthesis and apoptosis. 
Interestingly, downregulation of either Cry1 or Cry2 yield results similar to 
downregulation of both genes with regard to UV-induced p73 levels and the extent of 
apoptosis as probed by caspase activity (Fig. 9). Importantly, both of these effects are 
reversed by downregulation of BMAL1 (Fig. 9), supporting the conclusion that the 
expression of p73 is controlled both by DNA damage and by the circadian clock, a unique 
and unprecedented regulatory mechanism. 
Control of p73 Expression by DNA Damage and the Circadian Clock 
 Next, I wished to find out how clock disruption by Cry mutation leads to elevated p73 
levels. As this increase was dependent both on the circadian TTFL and DNA damage we 
investigated the p73 promoter for clock-related sequence elements. I found that the p73 
promoter region up to 4 kbp preceding the transcription initiation site did not reveal a 
canonical E-box or the variant E’-box elements which are key sequence elements in the 
promoters of most first-order clock-controlled genes. Then, I considered the possibility that 
p73 may be a second-order clock-controlled gene. The transcriptional regulation of p73 has 
been investigated in some detail. The gene is negatively controlled by C-EBPα and is 
activated by Egr1 (Early growth response1) (Marabese et al., 2003; Yu et al., 2007). 
Treatment of cells with DNA damaging agents leads to release of the repressive C-EBPα 
from the promoter and transcriptional upregulation of p73 in an Egr1-dependent manner. Of 
particular interest, it was recently reported that Egr1 might be a clock-controlled gene (Bai et 
al., 2008; Humphries and Carter, 2004). 
 These facts, considered together, lead to certain predictions: Egr1 must be regulated   
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Fig. 9. Regulation of p73-mediated apoptosis by the circadian clock. Enhanced apoptosis 
observed in cryptochrome-deficient cells is reversed by downregulation of BMAL1. The 
p53KO cells were transfected with the indicated siRNAs, UV irradiated where indicated with 
10 Jm-2 and apoptosis was probed by immunoblotting for cleaved PARP and cleaved caspase 
3. 
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Fig. 10. Downregulation of Period proteins (Per1 and 2) increases sensitivity of p53KO 
cells to UV-induced apoptosis. Cells transfected with the indicated siRNAs were irradiated 
with 10 Jm-2 where indicated and 24 hrs later were harvested and analyzed by 
immunoblotting for protein expression and apoptosis, and by RT-PCR for gene expression. 
Actin and GAPDH are internal controls for the immunoblots and the RT-PCR reactions, 
respectively. 
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in CryDKO cells and this upregulation must be reversed by downregulation of BMAL1. 
Secondly, it would be expected that BMAL1 will bind to the Egr1 promoter, and finally, both 
Egr1 and C-EBPα are expected to bind to the p73 promoter where the binding of C-EBPα but 
not of Egr1 must be affected by UV irradiation. 
 I tested these predictions in experiments summarized in Fig. 11 and 12. As would be 
predicted for a clock-controlled gene, the level of Egr1 is elevated both in CryDKO and 
p53KOCryDKO cells (Fig. 11A). Moreover, in accordance with the prediction, the elevation of 
Egr1 as a consequence of Cry downregulation can be reversed by BMAL1 knockdown (Fig. 
11B), consistent with regulation of Egr1 by the primary circadian feedback loop. In support 
of the model for positive regulation by BMAL1 and negative regulation by Cry, ChIP 
analysis reveals occupancy of the Egr1 E-box sequence element by BMAL1 which is 
enhanced in the absence of Cry1/2 and abolished by downregulation with BMLA1 (Fig. 11C). 
Finally, when the occupancy of the p73 promoter was analyzed by ChIP I found greatly 
enhanced occupancy by Egr1 in p53KOCryDKO cells, which was not affected by UV 
irradiation. (Fig. 12A). In contrast, Cry mutation had no effect on binding of C-EBPα to the 
p73 promoter but the occupancy of the promoter by C-EBPα was drastically reduced after 
UV irradiation (Fig. 12A). Taken together, these data support the model that p73 expression 
is regulated by the clock-controlled Egr1 and by the DNA damage-controlled C-EBPα and 
hence in Cry-null mutants increased expression of Egr1 combined with UV damage-induced 
dissociation of C-EBPα from the p73 promoter leads to a high level of p73 production and 
the consequent apoptosis. In further support of this model I found that both in p53KO and in 
p53KOCryDKO cells downregulation of Egr1 by siRNA significantly reduces UV induction of 
p73 and abolishes apoptosis (Fig. 12B). 
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Regulation of p73 by the Circadian Clock in Human Cancer Cell Lines 
 The apoptosis enhancing effect of Cry mutation seems to be unique to both mouse 
and human p53 mutant cells because in cells with wild-type p53 the p53-driven apoptosis is 
expected to be dominant and thus obscure any contribution of the p73 pathway (Flores et al., 
2002). 
 This prediction was tested by analyzing apoptosis in two p53 mutant and one p53 
wild-type human cancer cell lines. As seen in Fig. 12C in the Caco-2 and H1299 cell lines in 
which p53 is not functional, downregulation of Cry enhances p73 expression and increases 
apoptosis after UV irradiation. In contrast, in the A549 cell line with a functional p53 even 
though downregulation of Cry leads to enhanced levels of p73 after UV this upregulation of 
p73 is not accompanied by enhanced apoptosis (Fig. 12D) because apparently the UV-
induced p53 is sufficient to cause maximal level of apoptosis which cannot be further 
enhanced by increased p73. Taken together, the data in Fig. 11 and 12 show that Egr1 is a 
clock-controlled gene and that p73 is a second order clock-controlled gene that plays a 
prominent role in promoting apoptosis in p53-null cells lacking cryptochrome. 
Enhancement of the Efficacy of Oxaliplatin by Cryptochrome Disruption 
 Next, I wished to determine if the enhancement of apoptosis induced by genotoxic 
agents (intrinsic apoptosis) (Danial and Korsmeyer, 2004; Hotchkiss et al., 2009) by Cry 
mutation in p53 mutant cells can be used for therapeutic purposes. 
 Cisplatin and its second and third generation derivatives are UV-mimetic agents that 
kill cells mainly by producing intrastrand diadducts in DNA (Jung and Lippard, 2007; 
Kelland, 2007). Hence, I reasoned that cryptochrome disruption might enhance the sensitivity 
of p53-null cells and tumors to killing by platinum derivatives. 
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Fig. 11. Egr1 is a clock-controlled gene. (A) Overexpression of Egr1 in cryptochrome-
deficient cells. Mouse fibroblasts of the indicated genotypes were analyzed for expression of 
Egr1 and C-EBPα, the two main regulators of p73. Actin was used as a loading control. (B) 
Egr1 expression is regulated by the circadian clock. p53KO fibroblasts were transfected with 
the indicated siRNAs and the levels of Egr1 and C-EBPα were probed by immunoblotting. 
(C) Binding of BMAL1 (positive arm of the core circadian clock) to the Egr1 promoter. 
Fibroblasts of the indicated genotypes were transfected with control (Ctrl) or BMAL1 siRNA 
and then the occupancy of the Egr1 promoter by BMAL1 was analyzed by ChIP. Note the 
elevated ChIP values in p53KOCryDKO cells relative to p53KO cells, indicating that Cry reduces 
the occupancy of target promoters by BMAL1 (p<0.05, n=3). 
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Fig. 12. Requirement for Egr1 in the clock-mediated p73-dependent apoptosis. (A) 
Effect of UV on occupancy of p73 promoter by Egr1 and C-EBPα in the absence and 
presence of cryptochrome. Mouse fibroblasts of the indicated genotypes were irradiated with 
10 Jm-2 where indicated and the promoter binding of Egr1 and C-EBPα were determined by 
ChIP. Note that Cry mutation enhances Egr1 binding (p<0.05, n=3) which is not affected by 
UV. In contrast, Cry mutation has no effect on C-EBPα binding, which is significantly 
reduced by UV irradiation. (B) Elevated Egr1 in Cry mutant cells is responsible for enhanced 
UV-induced apoptosis. Mouse fibroblasts of the indicated genotypes were transfected with 
the indicated siRNAs, irradiated with UV and then analyzed for C-EBPα and p73 expression 
directly by immunoblotting, and for apoptosis by immunoblotting for cleaved PARP and 
caspase 3. (C) Effect of cryptochrome downregulation in p53-null human cell lines on Egr1 
and p73 expression and UV-induced apoptosis. The cell lines were transfected with the 
indicated siRNAs, irradiated with 10 Jm-2 of UV where indicated and probed for apoptosis by 
immunoblotting. (D) Effect of cryptochrome downregulation on Egr1 and p73 expression 
and UV-induced apoptosis in a human tumor cell line with wild-type p53. Whole cell lysates 
were analyzed by immunoblotting. 
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I performed our chemotherapy experiments with oxaliplatin which is the drug of 
choice for treating colorectal cancers among others (Kelland, 2007). First, I established that 
Cry mutation sensitizes transformed p53-null cells to oxaliplatin-induced p73 upregulation 
and to killing by apoptosis (Fig. 13). 
This was to be expected because the major DNA lesions induced by this drug, the GG, 
AG, and GXG diadducts can only be repaired by nucleotide excision repair as are the 
cyclobutane pyrimidine dimer and the (6-4) photoproduct (Gauger and Sancar, 2005). Then, I 
used a mouse tumor model to test the efficacy of oxaliplatin in treating clock-normal and 
clock-disrupted cancers by oxaliplatin. 
 Tumor xenografts were established in 6-week-old female immunodeficient mice by 
injection of oncogenically transformed p53KO and p53KOCryDKO cells (Ozturk et al., 2009). 
Each animal received, by subcutaneous injection, p53KO cells in one flank and p53KOCryDKO 
cells in the other. The tumors of both genotypes grew at the same rate (Fig. 14), and when the 
tumor volumes reached 0.1 cm3 oxaliplatin treatment was initiated. The mice received 10 
mg/kg oxaliplatin once a week for 3 weeks. Fig. 15A shows that administration of oxaliplatin 
drastically inhibits [18F]-FDG uptake in the p53KOCryDKO tumor compared to the p53KO 
tumor. In parallel with this effect on metabolism, oxaliplatin suppressed tumor growth in 
p53KOCryDKO but had no measurable effect on the growth rate of the p53KO tumor (Fig. 15B). 
 In vivo measurements of caspase 3 activity of the two groups of tumors after the drug 
treatment revealed that there was massive apoptosis in the tumor with the p53KOCryDKO 
genotype (Fig. 15C), which provides a mechanistic explanation of the favorable response to 
oxaliplatin of tumors of this genotype. Thus, the tumor xenograft study supports the 
prediction based on apoptosis and toxicity experiments with cultured cells that cryptochrome  
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Fig. 13. p53KOCryDKO cells are more sensitive to oxaliplatin-induced apoptosis and 
clonogenic killing than p53KO cells. (A) Induction of p73 by oxaliplatin. Cells of the 
indicated genotypes were treated with 0,2,5,10, or 20 µM oxaliplatin, harvested 24 hrs later 
and p73 induction was probed by immunoblotting. (B) Cells were treated with 0,5,10, or 20 
µM oxaliplatin, harvested 24 hrs later and analyzed for apoptosis by immunoblotting for 
PARP and caspase 3. (C) Clonogenic survival of oxaliplatin treated cells (±s.d., n=3). 
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Fig. 14. Growth rates of p53KO and p53KOCryDKO xenograft in NOD/SCID mice. Tumor 
xenografts were established by subcutaneous injection of 2×106 cells of a p53KO genotype on 
the left flank and a p53KOCryDKO genotype on the right flank in a 6-week-old female mouse. 
Tumor growth was monitored by a caliper and the size is plotted as a function of time after 
inoculation. The values are means ±s.d. (n=10). 
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Fig. 15. Effect of cryptochrome mutation on treating cancer with p53-null mutation. 
NOD/SCID mice bearing a p53KO tumor xenograft on the left flank (*) and a p53KOCryDKO 
tumor xenograft on the right flank (**) received oxaliplatin intraperitoneally at 10 mg/kg 
once a week for 21 days and various tumor-related metrics were recorded. (A) Tumor 
metabolism. MicroPET scan recorded 1 hr after [18F]-FDG injection on day 38 after 
xenograft injection. The right panel shows the quantification of [18F]-FDG signal calculated 
as the ratio of % injected dose (ID) at region of interest (ROI, circle) to the % ID at a 
background region. Error bars represent means ±s.d. (n=4). The dorsal aspect is shown. (B) 
Tumor growth. The arrows indicate days of oxaliplatin injection following the xenograft 
injection on day 0. The oxaliplatin treatment was initiated after tumor size had reached 0.1 
cm3. Error bars represent means ±s.d. (n=10). (C) Oxaliplatin-induced apoptosis in 
xenografts. The NOD/SCID mice were injected with p53KO-Luc cells in the left flank (*) and 
p53KOCryDKO-Luc cells in the right flank (**). One week later, weekly injections with 
oxaliplatin were initiated. After the third round of oxaliplatin injection, 2-DEVD-
aminoluciferin prosubstrate for caspase 3 was administered i.p. and 10 mins later, 
bioluminescence was measured in ROI (circle) drawn over the tumor. Quantitative analysis is 
in the right panel. Error bars represent means ±s.d. (n=4). 
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disruption in p53-null cells makes them more sensitive to chemotherapy by oxaliplatin. 
Conclusion 
In Fig. 16, I summarize the findings of this study: Egr1 is a clock-controlled gene and p73 is 
a second order clock-controlled gene which is regulated through Egr1 by the clock and 
through C-EBPα by the DNA damage response reaction. In the absence of Cry, Egr1 is 
elevated and upon DNA damage the release of C-EBPα from the p73 promoter leads to Egr1-
activated upregulation of p73 and thus p53-independent apoptosis. These findings suggest 
that in p53 mutant tumors, which constitute about 50% of all human tumors, targeted 
inhibition of Cry may improve the efficacy of platinum-based chemotherapy or of 
combination chemotherapy that includes cis-platinum drugs. 
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Fig. 16. Model for targeting the clock to improve the efficacy of oxaliplatin treatment of 
p53-null tumors. Cry regulates Egr1 which transactivates p73. With Cry inactive, Egr1 is 
upregulated. Following oxaliplatin induced removal of C-EBPα from the p73 promoter, Egr1 
causes massive production of p73 and enhanced apoptosis. 
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DISCUSSION 
 
 A previous report demonstrated that germline disruption of cryptochrome in p53-
deficient mice, which are highly tumor prone, increased their tumor-free survival (Ozturk et 
al., 2009). Notably, this effect was associated with an increase in DNA damage sensitivity of 
the p53-null and Cry-deficient tumor cells compared with those in p53-deficient tumor cells. 
These are interesting findings given the crucial role of p53 as a cellular executioner after 
DNA damage. When cells undergo irreparable DNA damage due to exposure to genotoxic 
stress such as UV radiation, the p53 protein activates transcription of proapoptotic target 
genes, effectively removing the damaged cells from the organism. Consequently, loss of p53 
in both humans and mice allows cells to persist and acquire new mutations necessary for 
cancer progression, yielding tumors that are refractory to our most common therapies, 
including ionizing radiation and chemotherapy. This previous report therefore suggested that 
loss of cryptochrome could reverse the DNA damage resistance induced by loss of p53. 
Killing such p53-deficient tumor cells is clearly one of the major challenges in cancer 
therapy. 
The model proposed herein provides insight into the mechanism by which 
cryptochrome deficiency sensitizes cells lacking p53 to apoptosis. I demonstrated that 
cryptochrome is involved in the regulation of the p53-related gene p73, which like p53 
functions as a tumor suppressor and helps maintain genomic integrity (Irwin et al., 2003; 
Tomasini et al., 2008; Wang et al., 2006). Transcription of p73, strong structural and 
functional similarity to p53, is enhanced in Cry-deficient cells in response to DNA damage. 
Loss of cryptochrome relieves repression of Clock/Bmal1, thereby leading to Egr1 up-
regulation and recruitment to the p73 promoter. Activation of p73 after cryptochrome loss 
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also requires the DNA damage-induced removal of the repressor C-EBPα from 
the p73 promoter. Thus, p73 is both temporally regulated by the circadian clock and acutely 
regulated in response to DNA damage. 
These findings may have significant implications in the field of cancer chronotherapy, 
which seeks to determine whether the effectiveness and tolerability of chemotherapy can be 
linked to the time of day treatment is given. Indeed, it has been found that treatment schedule 
can impact both long-term survival and nonspecific toxicity (Hrushesky, 1985; Levi et al., 
1990). However, the widespread application of such observations to standard clinical practice 
has been hampered by a lack of insight into how the circadian cycle influences the response 
to specific chemotherapeutic agents. I also demonstrated that p53-deficient tumor cells with 
cryptochrome disruption exhibit increased apoptosis and slower tumor growth in vivo after 
treatment with oxaliplatin. The finding that this effect is linked to p73 supports previous 
studies showing that platinum agents induce apoptosis at least in part through 
phosphorylation-dependent activation of p73 (Gong et al., 1999; Leong et al., 2007) and that 
p73 levels are a key determinant of chemosensitivity (Ibrahim et al., 2010; Irwin et al., 2003). 
It will therefore be of interest to determine whether the cryptochrome- and p73-dependent 
response is specific to treatment with platinum or will be seen with other common 
chemotherapeutic agents. 
 In addition to enhancing tumor chemosensitivity, these findings might also provide 
the strategy for approaches to limit the toxicity of chemotherapy for normal tissues. The 
model proposed herein suggests that in normal cells, the circadian cycling may result in a 
window when the amount of Egr1 bound to the p73 promoter is low, potentially blunting the 
apoptotic response of normal cells to chemotherapy. Interestingly, it has been found that 
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tumor cells in patients do not cycle with the same kinetics as their normal cells (Klevecz et 
al., 1987). Thus, an optimal treatment schedule might involve administration of DNA-
damaging agents when p73 levels are lowest in normal cells to reduce toxicity but higher in 
tumor cells to increase sensitivity. Interestingly, the DNA repair protein XPA is elevated 
in Cry-deficient mouse tissues, and as a result tissues of these mutant mice undergo more 
efficient nucleotide excision repair in response to cisplatin treatment than wild-type cells 
(Kang et al., 2010; Kang et al., 2011). Thus, although loss of cryptochromes makes p53-
deficient tumor cells more sensitive to chemotherapy, the opposite may be true in normal 
cells. This difference may be explained in part by the fact that in some cellular contexts, p53 
can mediate cell cycle arrest and DNA repair as opposed to inducing apoptosis. Thus, 
therapeutic targeting of cryptochrome function may allow for a coordinate increase in 
chemosensitivity of tumor cells and decrease in toxicity for normal cells. 
The results presented herein demonstrate that p53KOCryDKO tumors are more 
responsive to oxaliplatin than p53KO tumors. However, UV and oxaliplatin activate the 
intrinsic apoptosis pathway that is commonly induced by DNA damaging agents (Hotchkiss 
et al., 2009), whereas the difference in tumor incidence between the two mouse lines was 
observed in the absence of any external genotoxic stress. Formally, two biochemical 
pathways of apoptosis have been defined, extrinsic and intrinsic pathways (Hotchkiss et al., 
2009; Tait and Green, 2010). In the mitochondria-independent, extrinsic pathway, a member 
of the tumor necrosis factor family, such as TNFα, binds to its cognate death receptor in 
the plasma membrane causing clustering of the receptor and the cytoplasmic adaptor 
molecules, and as a consequence, dimerization of pro-caspase 8. The latter is activated by 
autoproteolysis in trans to generate initiator caspase 8, which in turn converts pro-caspase 
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3 to the executioner caspase 3 that dismantles cellular architecture, destroys some key 
cellular enzymes, and activates caspase activated DNase (CAD) which attacks chromosomes, 
generating the apoptosis signature feature, the “nucleosome ladder” (Enari et al., 1998; 
Sakahira et al., 1998). Of interest, recent work indicates that the core circadian clock 
participates in the extrinsic pathway by regulating the synthesis of TNFα (Hashiramoto et al., 
2010). Moreover, as TNFα is known to be involved in the inflammatory 
response, CryDKO mice which overexpress TNFα are uniquely sensitive to inflammatory 
stimuli and exhibit a rheumatoid arthritis-like syndrome caused by such stimuli (Keller et al., 
2009). Thus, it is conceivable that the loss of cryptochrome may amplify the extrinsic 
pathway for apoptosis to eliminate cells with potential to give rise to cancer. It will therefore 
be of interest to determine if the clock disruption through cryptochrome inhibition sensitizes 
the transformed cells to apoptosis by inflammatory cytokines such as TNFα. Clearly, this 
future study will provide further mechanistic explanations for the reduction of cancer risk in 
p53-deficient mice by the Cry mutation. 
In summary, this study describes a novel circadian clock controlled-apoptotic 
pathway at a mechanistic level, which drives the induction of apoptosis in p53-deficient 
cancer cells. Our findings suggest that cryptochrome inhibition may be used as an adjuvant in 
chemotherapy of p53-null cancer by genotoxic agents such as platinum-based drugs. 
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